These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36140265)

  • 41. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
    Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Establishment of a Novel Temozolomide Resistant Subline of Glioblastoma Multiforme Cells and Comparative Transcriptome Analysis With Parental Cells.
    Ha HA; Yang JS; Tsai FJ; Li CW; Cheng YD; Li J; Hour MJ; Chiu YJ
    Anticancer Res; 2021 May; 41(5):2333-2347. PubMed ID: 33952458
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biomimetic Polymer-Templated Copper Nanoparticles Stabilize a Temozolomide Intermediate for Chemotherapy against Glioblastoma Multiforme.
    Wang X; Hu A; Du K; Feng F
    ACS Appl Bio Mater; 2021 Nov; 4(11):8004-8012. PubMed ID: 35006781
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Temozolomide nanoparticles for targeted glioblastoma therapy.
    Fang C; Wang K; Stephen ZR; Mu Q; Kievit FM; Chiu DT; Press OW; Zhang M
    ACS Appl Mater Interfaces; 2015 Apr; 7(12):6674-82. PubMed ID: 25751368
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
    Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
    PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models.
    Valtorta S; Lo Dico A; Raccagni I; Gaglio D; Belloli S; Politi LS; Martelli C; Diceglie C; Bonanomi M; Ercoli G; Vaira V; Ottobrini L; Moresco RM
    Oncotarget; 2017 Dec; 8(68):113090-113104. PubMed ID: 29348889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
    Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
    Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.
    Du K; Xia Q; Heng H; Feng F
    ACS Appl Mater Interfaces; 2020 Aug; 12(31):34599-34609. PubMed ID: 32648735
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
    Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
    J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Temozolomide: An Overview of Biological Properties, Drug Delivery Nanosystems, and Analytical Methods.
    Dutra JAP; Luiz MT; Tavares Junior AG; Di Filippo LD; Carvalho SG; Chorilli M
    Curr Pharm Des; 2022; 28(25):2073-2088. PubMed ID: 35658888
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A
    J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
    Arcella A; Palchetti S; Digiacomo L; Pozzi D; Capriotti AL; Frati L; Oliva MA; Tsaouli G; Rota R; Screpanti I; Mahmoudi M; Caracciolo G
    ACS Chem Neurosci; 2018 Dec; 9(12):3166-3174. PubMed ID: 30015470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival.
    Huang B; Yu Z; Liang R
    BMC Neurol; 2021 Nov; 21(1):424. PubMed ID: 34724914
    [TBL] [Abstract][Full Text] [Related]  

  • 57. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Blood-brain barrier penetrating liposomes with synergistic chemotherapy for glioblastoma treatment.
    Zhang Y; Qu H; Xue X
    Biomater Sci; 2022 Jan; 10(2):423-434. PubMed ID: 34873606
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1.
    Wang S; Chen C; Li J; Xu X; Chen W; Li F
    J Neurol Sci; 2020 Jul; 414():116837. PubMed ID: 32334273
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
    Yu J; Gao G; Wei X; Wang Y
    BMC Cancer; 2022 Jul; 22(1):786. PubMed ID: 35850753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.